<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - GANCICLOVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>GANCICLOVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#handlingAndStorage" data-toggle="tab">Handling and storage</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local treatment of herpes simplex infections</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 5 times a day until healing complete, then apply 3 times a day for a further 7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of cytomegalovirus disease during immunosuppressive therapy following organ transplantation</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg/kg every 12 hours for 7&#8211;14 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients only</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg/kg every 12 hours for 14&#8211;21 days, followed by maintenance 6 mg/kg daily on 5 days of the week, alternatively 5 mg/kg daily until adequate recovery of immunity, maintenance only for patients at risk of relapse of retinitis, if retinitis progresses initial induction treatment may be repeated.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Avoid&#8212;teratogenic risk.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Reduce dose if eGFR less than 70&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; consult product literature.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Abnormally low haemoglobin count (consult product literature)</li>
            <li>abnormally low neutrophil count (consult product literature)</li>
            <li>abnormally low platelet count (consult product literature)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal pain, abnormal thinking, anaemia, anorexia, anxiety, arthralgia, chest pain, confusion, constipation, convulsions, cough, depression, dermatitis, diarrhoea, dizziness, dyspepsia, dysphagia, dyspnoea, ear pain, eye pain, fatigue, flatulence, headache, hepatic dysfunction, infection, injection-site reactions, insomnia, leucopenia, macular oedema, myalgia, nausea, night sweats, pancytopenia, peripheral neuropathy, pruritus, pyrexia, renal impairment, retinal detachment, taste disturbance, thrombocytopenia, vitreous floaters, vomiting, weight loss,
              </p>
              <p>
                <strong>uncommon:</strong> alopecia, anaphylactic reactions, arrhythmias, disturbances in hearing and vision, haematuria, hypotension, male infertility, mouth ulcers, pancreatitis, psychosis, tremor,
              </p>
              <p>
                <strong>notKnown:</strong> burning sensation, superficial punctate keratitis, tingling,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Infuse into vein with adequate flow preferably using plastic cannula.</p><p>For <i>intravenous infusion</i> (<i>Cymevene</i>
            <tm tmtype="reg"/>) give intermittently in Gluclose 5% or Sodium chloride 0.9%. Reconstitute initially in water for injections (500&#8239;mg/10&#8239;mL then dilute to not more than 10&#8239;mg/m with infusion fluid (usually 100&#8239;mL); give over 1 hour.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            children (possible risk of long-term carcinogenic or reproductive toxicity)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            ensure adequate hydration
          </li>
          <li>
              <strong>With intravenous use:</strong>
            history of cytopenia
          </li>
          <li>
              <strong>With intravenous use:</strong>
            potential carcinogen
          </li>
          <li>
              <strong>With intravenous use:</strong>
            potential teratogen
          </li>
          <li>
              <strong>With intravenous use:</strong>
            radiotherapy
          </li>
          <li>
              <strong>With intravenous use:</strong>
            vesicant
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Ensure effective contraception during treatment and barrier contraception for men during and for at least 90 days after treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor full blood count closely (severe deterioration may require correction and possibly treatment interruption).</p>
            </section>
      </section>




      <section class="tab-pane" id="handlingAndStorage">
        <h2>Advice regarding handling and storage</h2>

            <section class="handlingAndStorage">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Caution in handling</p>
              <p>Ganciclovir is toxic and personnel should be adequately protected during handling and administration; if solution comes into contact with skin or mucosa, wash off immediately with soap and water.</p>
            </section>
      </section>






      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients hypersensitive to valganciclovir, aciclovir, or valaciclovir.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of GANCICLOVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76735"><a href="../medicinalForm/PHP76735.html" data-target="#PHP76735" data-action="load">Powder for solution for infusion</a></div>
            <div id="PHP76727"><a href="../medicinalForm/PHP76727.html" data-target="#PHP76727" data-action="load">Eye gel</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
